Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment.
Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment.
复制标题
DOI：
10.1186/s40425-016-0134-0
复制
发表时间：
2016
影响因子：
10.9
通讯作者：
Nishino M
中科院分区：
文献类型：
--
作者：
Nishino M
霍迪等人最近的研究。发表在临床肿瘤学杂志上的文章使用免疫相关反应标准(IRRC)与RECIST1.1相比较，评估了PD-1抑制剂治疗期间的非常规反应模式，这构成了进一步了解免疫相关反应现象的重要一步。本评论讨论了研究中的关键意见的含义和缺陷，并描述了有待解决的未满足的需求。文章还强调了肿瘤反应标准作为描述癌症治疗结果的“共同语言”的重要作用，并讨论了免疫肿瘤学领域进一步发展的未来方向。
The recent study by Hodi et al. published in the Journal of Clinical Oncology has evaluated unconventional response patterns during PD-1 inhibitor therapy using immune-related response criteria (irRC) in comparison with RECIST1.1, which constitutes an important step to further understand immune-related response phenomena. This commentary discusses the key observations in the study in terms of their implications and pitfalls, and describes unmet needs that remain to be addressed. The article also emphasizes the important role of tumor response criteria as a “common language” to describe the results of cancer treatment, and discusses future directions for further advances of the field of immuno-oncology.